# Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients

> **NCT04835883** · PHASE2 · UNKNOWN · sponsor: **Hanyang University Seoul Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)

## Key facts

- **NCT ID:** NCT04835883
- **Lead sponsor:** Hanyang University Seoul Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-26
- **Primary completion:** 2021-11-05
- **Final completion:** 2026-01-20
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835883, "Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04835883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*